Medicare Compliance & Reimbursement - 2004 Issue 12
Drug Reimbursement: CMS Boosts Payments For Nine Drugs
Subscribe or sign in to view the full article.
Article Overview
This article reviews a CMS transmittal that increases payment rates for several physician-administered drugs after prior reimbursement concerns. It is relevant to oncology, ophthalmology, and other physician practices that bill for drug administration and want to understand the general scope of the CMS update and the categories of drugs affected.
Why This Topic Matters
The article highlights Medicare reimbursement changes that can materially affect practice costs, drug availability, and site-of-care decisions for physicians and cancer centers. It is useful for coders, billers, and practice managers tracking CMS payment policy for injectable and other covered drugs.
What You Will Learn
- The general CMS reimbursement update discussed in the article
- Which clinical areas are affected by the payment changes
- Why practices were concerned about prior payment levels
- The broad categories of drugs included in the transmittal
Who Should Read This
- Medical coders
- Medical billers
- Revenue cycle staff
- Oncology practice managers
- Physician practices
- Healthcare reimbursement professionals
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com